Biohit Oyj Press release, 15th February, 2018 at 9.30 a.m. local time (EET)

Biohit Oyj and Dow BioMedica have signed an agreement for the distribution of Biohit GastroPanel in Korea. The contract has been signed for four years with a continuation option. The registration will start during the 1st quarter of 2018.

CEO Young Gill Shin, Dow BioMedica Inc.: “Korea has high incidence of Helicobacter pylori infection caused atrophic gastritis and related risks such as gastric cancer. GastroPanel as a primary examination will find patients for further examination, and allows more cost-effective utilization of the scarce endoscopy resources due to the reduction of unnecessary gastroscopies. Dow BioMedica is very much proud to collaborate with Biohit healthcare.”

CEO Semi Korpela, Biohit Oyj: ”GastroPanel innovation is a highly accurate and cost-efficient examination in diagnosis of Helicobacter pylori infection and atrophic gastritis, the two prime risk factors of gastric cancer. GastroPanel has proven its suitability and efficacy as the first-line diagnostic test in numerous countries including China, which shares similar dyspepsia and stomach cancer incidence rates as Korea.”

Additional information: 
CEO Semi Korpela, Biohit Oyj
tel. +358 9 773 861 Rationale of the Biohit GI Panel

Biohit in brief

Biohit Oyj is a globally operating Finnish biotechnology company. Biohit’s mission is “Innovating for Health” – we produce innovative products and services to promote research and early diagnosis. Biohit is headquartered in Helsinki, Finland, and has subsidiaries in Italy and the UK. Biohit's Series B share (BIOBV) is quoted on Nasdaq Helsinki in the Small cap/Healthcare group.

Dow Biomedica in brief

Dow Biomedica is one of the leading diagnostic companies in Korea, and has been developing diagnostic market with novel biomarkers and new technologies e.g. next generation sequencing technology, free light chain assays, chromogranin A assay etc.